Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +81.98% and +15.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Fintel reports that on July 27, 2025, Barclays downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 214.11% Upside As of ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Sarepta between June 22, ...

On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta’s medication intended for ...